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Objective: Although various clinical factors that affect medication adherence in schizophrenia have been studied, the 
role of the therapeutic alliance has not been studied in detail. Accordingly, we investigated the association between 
medication adherence and therapeutic alliance in patients with schizophrenia treated in a community outpatient clinic 
in Korea.
Methods: In this cross-sectional study, 81 outpatients who met the DSM-IV-TR criteria for schizophrenia were analyzed. 
Therapeutic alliance was measured via patient-self-report questionnaires consisting of 12 questions, which evaluate both 
“affective bond” and “collaborative bond” of alliance. We investigated the relationship between medication adherence 
and therapeutic alliance through correlation and regression analyses.
Results: Overall therapeutic alliance was weakly associated with medication adherence (r=0.268, p＜0.05). Among two 
factors of therapeutic alliance, “affective bond” was associated with adherence (r=0.302, p＜0.05), but collaborative 
was not. Regression analysis showed that therapeutic alliance significantly predicted medication adherence even after 
adjustment for duration of treatment, insight, and symptom severity.
Conclusion: Maintaining a favorable therapeutic alliance is associated with medication adherence in schizophrenia. 
Further, treating patients in a frank and genuine manner might be important to improve adherence.
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INTRODUCTION
Patients with schizophrenia must take medicine on a 
regular basis to control acute positive symptoms and pre-
vent long-term relapse.1,2) However, many such patients 
do not follow their clinician’s recommendations and in-
stead stop taking medications. Among patients whose 
symptoms are alleviated via medication, 30% to 50% do 
not comply with their clinician’s prescriptions after symp-
toms are relieved,3) and 50% of inpatients stop taking 
medicines without discussion with their health care pro-
viders within 1 year of discharge.4) Moreover, patients 
with psychiatric disorders are known to have a higher ten-
dency to avoid taking their medications than are those 
with physical disorders.5) Non-adherence to medication 
in schizophrenia remains an unsolved problem that re-
duces patients’ quality of life and incurs a tremendous so-
cial cost.6) 
Various studies have been conducted to identify the de-
terminants of medication non-adherence in patients with 
schizophrenia.7-11) Impaired illness insight, one of the key 
features of schizophrenia, has consistently been reported 
to impact adherence to treatment.7,10,11) Suffering severe 
psychotic symptoms8) and comorbid substance use dis-
order12) also showed a significant relationship with non- 
adherence. The majority of adherence studies have con-
centrated on the characteristics of patients or disease-related 
characteristics, since non-adherence in schizophrenia has 
typically been regarded as an irrational behavior resulting 
274 J.G. Chang, et al.
from psychotic symptoms or lack of illness insight. Recently, 
interest in treatment environment factors has grown as it is 
known that patients’ attitudes to treatment have an im-
portant impact on adherence.13) Day et al.7) reported that 
modifying patient’s negative experiences of treatment 
could improve adherence through encouraging a positive 
attitude to treatment.
Therapeutic alliance refers to the collaborative and af-
fective intimacy between a between a therapist and his or 
her patient,14) and can affect patient’s attitude to treatment. 
Bordin15) conceptualized alliance as consisting of three 
components: goal agreement, task agreement, and affec-
tive bond. Studies have suggested that therapeutic alli-
ance is relevant to therapeutic outcomes, including medi-
cation adherence in various psychiatric disorders, such as 
depression16,17) and bipolar disorder.18) Nonetheless, few 
studies have explored adherence in schizophrenia. Studies 
regarding schizophrenia have targeted hospitalized pa-
tients12) or those in intensive therapy programs.19,20) In a 
recent study, McCabe et al.21) investigated the relationship 
between medication adherence and therapeutic alliance 
among outpatients with schizophrenia. However, the au-
thors did not consider important clinical factors, such as 
insight or symptom severity, as covariates. It remains un-
clear whether the therapeutic alliance from the patient’s 
perspective is associated with medication adherence in 
an outpatient clinical setting.
Accordingly, this research explored the relationship be-
tween medication adherence and therapeutic alliance in 
patients with schizophrenia attending routine outpatient 
clinics in Korea. We hypothesized that therapeutic alli-
ance from the patient’s perspective would be associated 
with better medication adherence. 
METHODS
Subjects
We performed a cross-sectional study of patients aged 
18 to 60 years who were diagnosed with schizophrenia 
according to the Diagnostic and Statistical Manual of 
Mental Disorders 4th edition, text revision (DSM-IV-TR) 
and considered to be stable.22) We defined a stable patient 
as one whose antipsychotic regimen had remained un-
changed for the previous 8 weeks and who was able to re-
spond to self-rating psychiatric scales appropriately. Data 
were collected at two outpatient clinics, namely Sever-
ance and Severance Mental Health Hospital. The clinics 
are located in urban and rural areas of Korea, respect-
ively. Patients were asked to participate in the research by 
one of the researchers, while patients were waiting to see 
their clinicians. Patients gave informed, voluntary written 
consent after the study procedure was fully described to 
them. This study was approved by the Severance Clinical 
Review Committee.
Assessments
To assess medication adherence, patients completed 
the Medication Adherence Rating Scale (MARS),13) which 
is a 10-item self-report scale that combines the Medication 
Adherence Questionnaire23) and Drug Attitude Inventory,24) 
and which has been validated in Korean patients with 
schizophrenia. It yields scores ranging from 0 to 10 
(perfect adherence).
The therapeutic relationship was assessed using the 
Scale to Assess the Therapeutic Relationship-Patients ver-
sion (STAR-P).25) STAR-P is a self-rating measure for pa-
tients that comprises 12 questions, each of which is rated 
on a 5-point Likert scale. Explanatory factor analysis by 
Kwon26) with a Korean population revealed the STAR-P 
has two-factor structures, consisting of 1) “collaborative 
bond” and 2) “affective bond.” Collaborative bond reflects 
shared understanding of goals and the experience of mu-
tual openness. Affective bond reflects the patient’s sub-
jective problems with the relationship, such as the pa-
tient’s perception that the clinician is impatient, author-
itarian, or withholds the truth. The questions addressing 
the affective bond factor were inverse-scored. A total 
score was obtained by summing the relevant subscale 
scores. Higher ratings indicated a better alliance.
Insight was measured using the Scale to Assess 
Unawareness of Mental Disorder (SUMD).27) SUMD has 
three items to assess the awareness of having a mental dis-
order (item 1), the effect of medication (item 2), and the 
consequences of the mental disorder (item 3). Items are 
rated from 1 to 5, with higher ratings indicating lower 
insight. We used the sum of all items to provide a global 
insight score.
Ratings of psychopathology were obtained by trained 
and experienced clinicians when patients agree to partic-
ipate in the study, using the Brief Psychiatric Rating Scale 
(BPRS).28) Global functioning was assessed via the Global 
Assessment of Functioning Scale (GAF).19) Sociodemo-
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Table 2. Correlations between therapeutic alliance and clinical variables
Variable 
STAR-P
Total Collaborative bond Affective bond
Symptom severity (BPRS) −0.236* −0.288* −0.211
Insight (SUMD) −0.125 −0.079 0.062
Global functioning (GAF) 0.060 0.014 0.099
Medication adherence (MARS) 0.268* 0.050 0.302*
STAR-P, Scale to Assess the Therapeutic Relationship-Patients version; BPRS, Brief Psychiatric Rating Scale; SUMD, Scale to Assess Unawareness 
of Mental Disorder; GAF, Global Assessment of Functioning; MARS, Medication Adherence Rating Scale. 
Table entries are Pearson correlations coefficients; significant at *p＜0.05. 
Table 1. Clinical characteristics of the study population (n=81)
Variable Data
Symptom severity (BPRS) 27.31±9.708 (5-50)
Insight (SUMD) 7.09±2.091 (3-15)
Global functioning (GAF) 52.77±9.705 (50-70)
Therapeutic alliance (STAR-P) 45.04±9.594 (26-60)
Medication adherence (MARS) 6.81±2.71 (3-15)
Values are presented as mean±standard deviation (range).
BPRS, Brief Psychiatric Rating Scale; SUMD, Scale to Assess Un-
awareness of Mental Disorder; GAF, Global Assessment of Func-
tioning; STAR-P, Scale to Assess the Therapeutic Relationship- 
Patients version; MARS, Medication Adherence Rating Scale.
graphic characteristics of the participants were also 
obtained. 
Analysis
Descriptive statistics were obtained for clinical and so-
cio-demographic variables. Associations between the 
therapeutic alliance and clinical/socio-demographic vari-
ables were explored using t tests and bivariate correlations.
We examined the association between therapeutic alli-
ance and medication adherence through regression analysis. 
We used therapeutic alliance as the independent varia-
ble, with covariates potentially associated with adherence 
of duration of illness, insight, and symptom severity.11) 
Statistical significance was set at p＜0.05. All statistical 
analyses were performed using SPSS version 23 software 
(IBM Corp., Armonk, NY, USA).
RESULTS
Participants
Eighty-one patients participated in the study, of whom 
36 (44.4%) were male. The mean age of the participants 
was 38.02 years (standard deviation [SD], 10.07). Sixty of 
the participants were single (74.1%). The patients had re-
ceived treatment for a mean of 11.29 years (SD, 7.67) and 
had previously been hospitalized an average of 3.05 
times. Table 1 shows the clinical characteristics of the 
participants.
Association between Therapeutic Alliance and Socio- 
demographic Characteristics
There was no difference in therapeutic alliance accord-
ing to sex and marital status. The results of correlation 
analysis also showed no significant association between 
therapeutic alliance and age, illness duration, or admis-
sion frequency (data not shown).
Association between Therapeutic Alliance and Other 
Clinical Variables
Table 2 shows the results of a correlation analysis be-
tween therapeutic alliance and insight, symptom severity, 
and medication adherence. Therapeutic alliance was not 
associated with insight but was negatively associated with 
symptom severity. Of the two factors constituting ther-
apeutic alliance, non-supportive clinical input was asso-
ciated with medication adherence, but collaboration was 
not.
Therapeutic Alliance and Adherence
According to univariate analysis, favorable therapeutic 
alliance predicted better medication adherence (B=0.054, 
beta=0.268, t=2.310, p=0.024). Significance was main-
tained after adjustment for covariates including duration 
of illness, insight, and symptom severity (Table 3).
DISCUSSION
In the present study, we identified a relationship be-
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Table 3. Linear regression results for medication adherence by therapeutic alliance
Medication adherence (MARS)
B Beta t p R2
Therapeutic alliance (STAR-P) 0.060 0.277 2.526 0.014 0.318
Duration of illness 0.097 0.392 3.693 0.000
Symptom severity (BPRS) 0.024 0.106 0.954 0.344
Insight (SUMD) −0.188 −0.253 −2.404 0.019
MARS, Medication Adherence Rating Scale; STAR-P, Scale to Assess the Therapeutic Relationship-Patients version; BPRS, Brief Psychiatric Rating 
Scale; SUMD, Scale to Assess Unawareness of Mental Disorder. 
tween therapeutic alliance and medication adherence in 
patients with schizophrenia. Patients who reported hav-
ing a better therapeutic alliance with their clinician 
showed favorable medication adherence, even after ad-
justment for factors that might have affected adherence. 
This is one of the few studies to have investigated the role 
of therapeutic alliance on medication adherence from the 
perspective of patients with schizophrenia who were re-
ceiving treatment via routine outpatient clinics.
The results of our study are consistent with those of pre-
vious studies that investigated the association between 
therapeutic relationship and medication adherence.12,21) 
However, the correlation between patient-rated ther-
apeutic alliance and medication adherence was very 
weak. Moreover, among the two factors that underlie 
therapeutic alliance, collaboration had no relevance to 
adherence. This result indicates that active discussions 
about treatment goals between clinicians and patients 
had limited impact on adherence. McCabe et al.21) re-
ported that therapeutic alliance from the patient’s per-
spective had a weaker association with adherence than 
did this alliance from the clinician’s perspective. These re-
sults suggest that patients with schizophrenia take medi-
cation passively via the mental service environment, rath-
er than having their own treatment goals. Among the two 
components of therapeutic alliance, patients’ affective 
bond showed the stronger association with medication 
adherence. Lack of affective bond refers to the patient’s 
perception of the clinician as impatient, authoritarian, 
and liable to withhold the truth. This result is consistent 
with Day et al.,7) who showed that patient’s coercive ex-
periences during admission were an important determi-
nant of adherence to medication. Nelson et al.29) also 
found that the patient’s perception of the physician’s in-
terest in him or her as a person was the single best pre-
dictor of medication adherence among discharged pa-
tients with schizophrenia. There is a power imbalance be-
tween the clinicians and patients in Korea; 75.9% of pa-
tients with schizophrenia are admitted involuntarily.30) 
This suggests that it is difficult to form positive affective 
bonds that foster medication adherence with patients with 
schizophrenia.
The participants showed favorable adherence in this 
study. Although there is no absolute cutoff value in MARS, 
the total score of our study was quite high (6.81). When 
Fialko et al.31) performed large scale validation study with 
an outpatient clinic, the average score of MARS was 6. In 
a survey of patient with homeless schizophrenia in 
France, the MARS average score was 5.5.32) Since our 
study was conducted on patients with relatively favorable 
adherence, further study examining the impact of ther-
apeutic alliance in patients with low adherence is also 
needed.
In the present study, therapeutic alliance was not asso-
ciated with insight. This result is inconsistent with other 
studies; most studies that investigated insight and ther-
apeutic alliance found a significant positive association 
between these two variables.33) This discrepancy might be 
because the participants in our study had limited varia-
bility in insight scores. Similar results were obtained in 
other studies that reported low among-patient variance in 
insight scores.34)
There are several difficulties in conducting research on 
medication adherence in patients with schizophrenia. 
Medication adherence is not only hard to define, but also 
difficult to assess. Adherence is a set of behaviors and 
habits that is dynamic and varies even within individuals, 
and it cannot be measured dichotomously. Furthermore, 
since those with poor adherence may also be likely to re-
fuse to participate in a study, selection bias inevitably 
exists. To solve these difficulties, we used MARS to meas-
ure medication adherence continuously, which is a com-
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prehensive tool for evaluating patients’ behavior and 
attitudes.13) Furthermore, since this study was conducted 
by interviewers who were not involved in the participants’ 
treatment, selection bias should not have been sizable. A 
further study that considers patients’ consent rates may be 
helpful to understand adherence.
There are some limitations other than the selection bias 
already mentioned. First, the cross-sectional design lim-
ited the ability to draw inferences with respect to the caus-
al direction of associations between adherence and ther-
apeutic alliance, which were considered to be dynamic 
factors. Second, we did not consider some clinical varia-
bles that are known to affect adherence, such as comorbid 
substance use disorder and treatment regimen. However, 
since we used insight level as a covariate, we were able to 
understand more about the impact of therapeutic alliance 
on adherence. Nevertheless, to our knowledge, this study 
is one of the few studies to have examined the effect of 
therapeutic alliance on medication adherence. Moreover, 
this study reflected the routine outpatient clinical setting 
and considered confounding factors that could affect 
adherence.
In conclusion, medication adherence among patients 
with schizophrenia patients who were treated in a routine 
outpatient clinic was influenced by therapeutic alliance. 
These findings suggest that it is important to establish a 
genuine and humanistic relationship between clinicians 
and patients to improve medication adherence.
The authors would like to thank all of the staff at 
Severance Hospital for their assistance with this research. 
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